Prostate Cancer

Adjuvant versus early salvage radiotherapy: outcome of patients with prostate cancer treated with postoperative radiotherapy after radical prostatectomy.

Adjuvant (ART) and salvage radiotherapy (SRT) are two common concepts to enhance biochemical relapse free survival (BCRFS) in patients with prostate cancer (PC). We analyzed differences in outcome between ART and SRT in patients with steep decline of PSA-levels after surgery to compare outcome.

Exploring health behaviors, quality of life, and support needs in African-American prostate cancer survivors: a pilot study to support future interventions.

Prostate cancer incidence and mortality rates are highest among African-American men. Comorbidity burden and quality of life (QOL) challenges are also high. Many factors drive these differences; health behaviors are important modifiable contributors.

Corticosteroid switch after progression on abiraterone acetate plus prednisone.

Abiraterone acetate plus prednisone is approved in metastatic castration-resistant prostate cancer. There is some evidence in favour of the steroid switch from prednisone to dexamethasone in patients who progressed whilst on abiraterone acetate plus prednisone or prednisolone.

Magnetic resonance image-guided focal laser ablation in clinically localized prostate cancer: safety and efficacy.

To evaluate the safety and efficacy of focal laser ablation (FLA) in low-intermediate risk prostate cancer.

Inclusion criteria were men aged 50-75 years, prostate-specific antigen (PSA) ≤15 ng/mL, clinical stage T1c-T2a, one or two lesions (PI-RADS ≥3) on magnetic resonance imaging (MRI), and Gleason score 6 (>3 mm) or Gleason 7 on targeted biopsy.

Novel agents for metastatic hormone-sensitive prostate cancer - A practice guide for urologists.

The last five years has witnessed a remarkable evolution in the management of metastatic hormone-sensitive prostate cancer (mHSPC), with multiple agents demonstrating profound benefit in combination with initial androgen deprivation therapy (ADT).

Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 1: Acquisition - Beyond the Abstract

The success of multiparametric magnetic resonance imaging (mpMRI) for reliably detecting and localizing clinically significant (cs) prostate cancer (PCa) is highly dependent on image quality. However, due to the variability of available MRI equipment including software levels and prostate MRI technologists’ (MRI radiographers’) experience, it can be challenging to consistently achieve good-quality images for detection, localization, staging, and follow-up of PCa. The first step to improve quality and reduce variability is to implement optimized acquisition protocols.

Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer.

To evaluate focal high dose rate (HDR) brachytherapy in locally recurrent prostate cancer.

Patients with biochemical relapse after non-surgical primary treatment for localised prostate cancer were selected after a negative screen for metastatic disease.

Questioning the status quo: Should Gleason Grade Group 1 prostate cancer be considered a "negative core" in pre-radical prostatectomy risk nomograms? An international multicenter analysis.

To assess the impact of excluding Gleason Grade Group 1 (GG1) prostate cancer (PCa) cores from current pre-radical prostatectomy (RP) nomograms.

Multi-institutional retrospective chart review performed on all RP patients with prostate biopsy between 2008-2018.

Real-world outcome with abiraterone acetate plus prednisone in Asian men with metastatic castrate-resistant prostate cancer: The Singapore experience.

Several small studies have reviewed the efficacy of abiraterone acetate plus prednisolone (AAP) in clinical practice outside a trial setting. We report the largest cohort study of clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC) patients treated with AAP in a multicenter multiracial clinical setting.

T-staging of prostate cancer: Identification of useful signs to standardize detection of posterolateral extraprostatic extension on prostate MRI.

To determine the prevalence and predictive value of a series of commonly used MRI criteria for posterolateral extraprostatic extension (EPE) of prostate cancer (PCa).

The presence of EPE in index lesions visible on prebiopsy mpMRI (T2w, DWI and DCE on a 3 Tesla-system) of biopsy-proven PCa patients was blindly assessed retrospectively by two radiologists with 8- and 17-years of experience on the basis of 8 commonly used staging criteria.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.